digital therapeutics

By Laura Lovett 04:39 pm June 7, 2018
A drug no longer needs to be a tangible object, according to panelist at the BIO 2018 convention in Boston. The way the pharma industry looks at medication is evolving and may be including new tech-focused treatments, such as digital therapeutics. “If you think about the trajectory of medicine what is a drug these days: is it a pill, is it an injection, is it infusion, is it gene therapy? We’ve...
By Dave Muoio 04:43 pm June 6, 2018
Stakeholders across healthcare are beginning to weigh the benefits and challenges digital therapeutics could bring to their businesses, and pharma is no exception. During an afternoon roundtable session held Wednesday at BIO 2018 in Boston, a panel of digital medicine and pharmaceutical representatives discussed the impact that these novel medicines has had, and could have, on drugmakers,...
By Dave Muoio 04:03 pm May 30, 2018
Today, Madison, Wisconsin-based digital respiratory health company Propeller Health announced a $20 million funding round led by a $10 million investment from Aptar Pharma. Existing investors Safeguard Scientifics, Social Capital, Hikma Ventures, 3M Ventures, and SR One comprised the other half of the round. According to a release, the new funding will be invested into the company’s digital...
By Jonah Comstock 08:59 am May 22, 2018
San Francisco-based Hinge Health has completed a randomized control trial of its digital care program for chronic knee pain. Results were promising, with users of the digital platform outperforming the control group in every outcome measure, though there was some loss of engagement among the study group. “It was really strong results,” CEO Daniel Perez told MobiHealthNews. “It was a trial that...
By Dave Muoio 04:18 pm May 18, 2018
Although it hasn’t yet established its place as a mainstream treatment modality, virtual reality has grown from an interesting diversion into a frequent topic of conversation within digital health. As researchers continue to dig their teeth into the immersive technology, it’s becoming clear that this new tool, often associated with video gaming and entertainment, could play a role in addressing...
By Dave Muoio 10:05 am May 9, 2018
This morning, Boston-based Akili Interactive Labs announced the closure of a $55 million Series C funding round. The investment was led by Temasek, with participation from Baillie Gifford, Amgen Ventures, M Ventures, JAZZ Venture Partners, Canepa Advanced Healthcare Fund, and Brooklands Capital Strategies. According to the company, this new funding will be used to support development, regulatory...
By Dave Muoio 04:24 pm March 21, 2018
A small, 6-week retrospective study published in JMIR mHealth and uHealth found that a behavior health-focused videogame developed by digital health company Litesprite improved self-reported measures of depression, anxiety, and confidence in coping skills. “What was unique and remarkable about the study is the participants using Sinasprite were completely self-directed and received no clinician...
By Jonah Comstock 04:56 pm March 12, 2018
Digital therapeutics may be up and coming, but they also have a long way to go before their mainstream treatment options, according to experts who spoke at the digital therapeutics deep dive at HIMSS18. “This is going to be a completely new industry sector,” Pierre Leurent, CEO of Voluntis, said during the session. “It’s going to have very strong growth in the years to come and it’s going to be a...
By Dave Muoio 04:11 pm March 2, 2018
 From syringes to workflow management systems, healthcare is no stranger to adopting new technologies into standard care. As digital and connected technologies continue to stake their claim in the industry, the last few years have seen the rise of a new type of health technology product — one that promises measurable health outcomes validated by traditional clinical trials.   “You had a little...
By Jonah Comstock 03:36 pm March 1, 2018
Pear Therapeutics has inked a deal with pharma company Novartis to work together on the development of two digital therapeutics for multiple sclerosis and schizophrenia. It’s the first time a pharma company has made a development deal with a digital therapeutic, according to Pear. “We have been in discussions for many months now with the [Novartis Institutes for BioMedical Research] group at...